Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Evaluation of Elafin Immunohistochemical Expression as Marker of Cervical Cancer Severity

Texto completo
Autor(es):
Longatto-Filho, Adhemar [1, 2, 3] ; Fregnani, Jose Humberto [4] ; da Costa, Allini Mafra [1, 5] ; de Araujo-Souza, Patricia Savio [6] ; Scapulatempo-Neto, Cristovam [1, 7] ; Herbster, Suellen [8] ; Boccardo, Enrique [8] ; Termini, Lara [9]
Número total de Autores: 8
Afiliação do(s) autor(es):
[1] Pio XII Fdn, Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos - Brazil
[2] Univ Sao Paulo, Sch Med, Dept Pathol, Lab Med Invest LIM 14, Sao Paulo, SP - Brazil
[3] Univ Minho, ICVS 3Bs, Life & Hlth Sci Res Inst, Sch Med, Braga - Portugal
[4] AC Camargo Canc Ctr, Sao Paulo, SP - Brazil
[5] Int Agcy Res Canc, Canc Surveillance Sect, Lyon - France
[6] Univ Fed Parana, Dept Genet, Lab Immunogenet & Histocompatibil, Curitiba, Parana - Brazil
[7] DASA Labs, Pathol & Mol Diagnost GeneOne, Sao Paulo, SP - Brazil
[8] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo, SP - Brazil
[9] Univ Sao Paulo, Ctr Invest Translac Oncol, Inst Canc Estado Sao Paulo, Hosp Clin, Fac Med, Sao Paulo, SP - Brazil
Número total de Afiliações: 9
Tipo de documento: Artigo Científico
Fonte: ACTA CYTOLOGICA; DEC 2020.
Citações Web of Science: 0
Resumo

Introduction: The main risk factor for the development of cervical cancer (CC) is persistent infection by human papillomavirus (HPV) oncogenic types. In order to persist, HPV exhibits a plethora of immune evasion mechanisms. PI3/Elafin (Peptidase Inhibitor 3) is an endogenous serine protease inhibitor involved in epithelial protection against pathogens. PI3/Elafin's role in CC is still poorly understood. Materials and Methods: In the present study, we addressed PI3/Elafin protein detection in 123 CC samples by immunohistochemistry and mRNA expression in several datasets available at Gene Expression Omnibus and The Cancer Genome Atlas platforms. Results: We observed that PI3/Elafin is consistently downregulated in CC samples when compared to normal tissue. Most of PI3/Elafin-positive samples exhibited this protein at the plasma membrane. Besides, high PI3/Elafin expression at the cellular membrane was more frequent in in situ stages I + II than in invasive cervical tumor stages III + IV. This indicates that PI3/Elafin expression is gradually lost during the CC progression. Of note, advanced stages of CC were more frequently associated with a more intense PI3/Elafin reaction in the nuclei and cytoplasm. Conclusion: Our results suggest that PI3/Elafin levels and subcellular localization may be used as a biomarker for CC severity. (AU)

Processo FAPESP: 08/57889-1 - Instituto de Ciência e Tecnologia para o Estudo das Doenças Associadas ao Papilomavírus
Beneficiário:Luisa Lina Villa
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 05/57274-9 - Identificação de marcadores de progressão tumoral em amostras do colo uterino e sua associação com a infecção por diferentes tipos de HPV
Beneficiário:Lara Termini
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 18/22097-0 - Neoplasias malignas nas 18 cidades pertencentes à regional de saúde de Barretos, São Paulo: a importância de um Registro de Câncer de Base Populacional
Beneficiário:Allini Mafra da Costa
Linha de fomento: Bolsas no Brasil - Pós-Doutorado